ORION

What is the study design of ORION 9, 10 11?

• 18-month study medication was given to participants on maximally tolerated background lipid-lowering therapy

• 24-month study medication was given to participants on maximally tolerated background lipid-lowering therapy

• 18-month study medication was given to participants on minimally tolerated background lipid-lowering therapy

• Phase I, single-dose, open-label, parallel-group study in participants with normal / impaired renal function

What are the co-primary endpoints of ORION 9, 10 and 11 Studies?

• Percentage change in LDL-C levels from baseline to Day 510

• Absolute change in LDL-C from baseline to Day 510

• Time-adjusted percentage change in LDL-C levels from baseline after Day 90 and Day 540

• Safety and tolerability profile of inclisiran

What type of patients were included in the ORION 9 Study?

• clinical ASCVD

• ASCVD and ASCVD risk equivalent

• Heterozygous familial hypercholesterolemia

• homozygous familial hypercholesterolemia

What type of patients were included in the ORION 10 study?

• clinical ASCVD patients

• ASCVD and ASCVD risk equivalent

• heterozygous familial hypercholesterolemia

• homozygous familial hypercholesterolemia

What type of patients were included in the ORION 11 Study?

• ASCVD patients

• ASCVD or ASCVD risk equivalent

• FH

• all of the above

What is the effective LDL reduction at month 17 in ORION 9 Study?

• 47.9%

• 44.3%

• 55%

• 70%

In the ORION 10 Study, what is the effective LDL reduction at month 17 on ASCVD patients?

• 54%

• 52%

• 70%

• 100%

What is the effective LDL reduction at month 17 in the ORION 11 Study in patients with ASCVD and risk equivalents?

• 50%

• 54%

• 49%

• 45%

In the pooled analysis of ORION 9, 10 and 11 Studies, how many percent of patients achieved target threshold of <70mg/dl at any post baseline visit?

• 90%

• 87%

• 68%

• 50%

In the pooled analysis of ORION 9, 10 and 11 Studies, treatment emergent AEs and SAEs were generally similar between inclisiran and placebo groups except for injection site reactions.

• True

• False